Integrated BioPharma (INBP) 10-Q 14 May 15 2015 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Mar. 31, 2015	14-May-15
Entity Registrant Name	INTEGRATED BIOPHARMA INC
Entity Central Index Key	1016504
Current Fiscal Year End Date	-24
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		21,105,174
Document Type	10-Q
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q3
Amendment Flag	FALSE

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Sales, net	$9,671	$7,522	$28,544	$25,501
Cost of sales	8,772	6,795	25,088	21,708
Gross profit	899	727	3,456	3,793
Selling and administrative expenses	887	923	2,595	2,710
Operating income (loss)	12	-196	861	1,083
Other income (expense), net
Interest expense	-251	-237	-741	-731
Change in fair value of derivative liabilities	41	10	702	19
Other income	116		143	5
Other income (expense), net	-94	-227	104	-707
(Loss) income before income taxes	-82	-423	965	376
Income tax expense, net	24	27	120	131
Net (loss) income	-106	-450	845	245
Change in fair value of derivative liability	-41	-10	-702	-19
Interest expense on Convertible debt-CD Financial, LLC			244
Accretion of Convertible debt - CD Financial, LLC			83
Diluted net (loss) income	($106)	($450)	$470	$245
Basic net (loss) income per common share (in dollars per share)	($0.01)	($0.02)	$0.04	$0.01
Diluted net (loss) income per common share (in dollars per share)	($0.01)	($0.02)	$0.02	$0.01
Weighted average common shares outstanding - basic (in shares)	21,105,174	21,080,174	21,105,174	21,080,174
Add: Stock options (in shares)			66,592	79,745
Shares issuable upon conversion of Convertible Debt - CD Financial, LLC (in shares)			8,230,769
Weighted average common shares outstanding - diluted (in shares)	21,105,174	21,080,174	29,402,535	21,159,919

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Mar. 31, 2015	Jun. 30, 2014
In Thousands, unless otherwise specified
Current Assets:
Cash	$354	$451
Accounts receivable, net	2,788	2,179
Inventories	5,887	5,698
Investment in iBio, Inc. - restricted	532	532
Other current assets	433	306
Total current assets	9,994	9,166
Intangible assets, net	777	880
Property and equipment, net	1,431	1,239
Security deposits and other assets	218	298
Total Assets	12,420	11,583
Current Liabilities:
Advances under revolving credit facility	4,412	4,121
Accounts payable (includes $210 and $184 due to related party)	5,828	5,635
Accrued expenses and other current liabilities	1,474	1,309
Current portion of long term debt	828	588
Total current liabilities	12,542	11,653
Long term debt	4,080	4,359
Subordinated convertible note, net - CD Financial, LLC	5,092	5,009
Derivative liabilities	15	717
Total liabilities	21,729	21,738
Commitments and Contingencies
Stockholders' Deficiency:
Common Stock, $0.002 par value; 50,000,000 shares authorized; 21,140,074 and 21,105,174 shares issued and outstanding, respectively	42	42
Additional paid-in capital	44,572	44,572
Accumulated deficit	-53,824	-54,670
Less: Treasury stock, at cost, 34,900 shares	-99	-99
Total Stockholders' Deficiency	-9,309	-10,155
Total Liabilities and Stockholders' Deficiency	$12,420	$11,583

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) (USD $)	Mar. 31, 2015	Jun. 30, 2014
In Thousands, except Share data, unless otherwise specified
Due to related party	$210	$184
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, authorized (in shares)	50,000,000	50,000,000
Common stock, issued (in shares)	21,140,074	21,140,074
Common stock, outstanding (in shares)	21,105,174	21,105,174
Treasury stock, shares (in shares)	34,900	34,900

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Cash flows provided by operating activities:
Net income	$845	$245
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	304	297
Accretion of financing instruments and other non-cash interest	179	177
Change in fair value of derivative liabilities	-702	-19
Gain on sale of fixed assets	-3	-4
Changes in assets and liabilities:
Accounts receivable	-608	479
Inventories	-189	1,763
Other current assets	-127	-30
Security deposits and other assets	-14	4
Accounts payable	193	-977
Accrued expenses and other liabilities	166	162
Net cash provided by operating activities	44	2,097
Cash flows from investing activities:
Purchase of property and equipment	-227	-115
Net cash used in investing activities	-227	-115
Cash flows from financing activities:
Advances under revolving credit facility	27,640	24,133
Repayments of advances under revolving credit facility	-27,349	-25,255
Proceeds from Line of Credit Note	307
Repayments under term note payables	-404	-699
Repayments under capital lease obligations	-108	-32
Net cash provided by (used in) financing activities	86	-1,853
Net (decrease) increase in cash	-97	129
Cash at beginning of period	451	55
Cash at end of period	354	184
Supplemental disclosures of cash flow information:
Interest	539	537
Income taxes	46	7
Supplemental disclosures of non-cash transactions:
Accretion on embedded derivative feature of convertible note payable	82	81
Amortization of prepaid financing costs	97	97
Financing on capitalized lease obligations	$185	$76

Note_1_Principles_of_Consolida

Note 1 - Principles of Consolidation and Basis of Presentation	9 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1. Principles of Consolidation and Basis of Presentation
	Basis of Presentation of Interim Financial Statements
	The accompanying condensed consolidated financial statements for the interim periods are unaudited and include the accounts of Integrated BioPharma, Inc., a Delaware corporation (together with its subsidiaries, the “Company”). The interim condensed consolidated financial statements have been prepared in conformity with Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and therefore do not include information or footnotes necessary for a complete presentation of financial position, results of operations and cash flows in conformity with accounting principles generally accepted in the United States of America. However, all adjustments (consisting only of normal recurring adjustments) which are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the periods presented have been included. These condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto, together with Management’s Discussion and Analysis of Financial Condition and Results of Operations, contained in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2014 (“Form 10-K”), as filed with the SEC. The June 30, 2014 balance sheet was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America. The results of operations for the three and nine months ended March 31, 2015 are not necessarily indicative of the results for the full fiscal year ending June 30, 2015 or for any other period.
	Nature of Operations
	The Company is engaged primarily in manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. The Company’s customers are located primarily in the United States, Luxembourg and Canada. The Company was previously known as Integrated Health Technologies, Inc. and, prior to that, as Chem International, Inc. The Company was reincorporated in its current form in Delaware in 1995. The Company continues to do business as Chem International, Inc. with certain of its customers and certain vendors.
	The Company’s business segments include: (a) Contract Manufacturing operated by InB:Manhattan Drug Company, Inc. (“MDC”), which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers; (b) Branded Proprietary Products operated by AgroLabs, Inc. (“AgroLabs”), which distributes healthful nutritional products for sale through major mass market, grocery, drug and vitamin retailers, under the following brands: Naturally Noni, Coconut Water, Aloe Pure, Peaceful Sleep, Green Envy, ACAI Extra, ACAI Cleanse, Wheatgrass and other products which are being introduced into the market (these are referred to as our branded proprietary nutraceutical business and/or products); and (c) Other Nutraceutical Businesses which includes the operations of (i) The Vitamin Factory (the “Vitamin Factory”), which sells private label MDC products, as well as our AgroLabs products, through the Internet, (ii) IHT Health Products, Inc. (“IHT”) a distributor of fine natural botanicals, including multi minerals produced under a license agreement and (iii) Chem International, Inc., a distributor of certain raw materials for DSM Nutritional Products, LLC.
	Significant Accounting Policies
	There have been no material changes during fiscal year 2015 in the Company’s significant accounting policies to those previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2014.
	Investment in iBio, Inc
	.
	The Company accounts for its investment in iBio, Inc. (“iBio”) common stock on the cost basis as it initially retained approximately 6% of its interest in iBio (1,266,706 common shares) (the “iBio Stock”) at the time of the spin-off of this subsidiary in August 2008.  The Company reviews its investment in iBio for impairment and records a loss when there is deemed to be an impairment of the investment. To date, there were cumulative impairment charges of $298. The market value of the iBio Stock as of March 31, 2015 was approximately $1.0 million.
	Pursuant to the Company’s Loan Agreement with PNC Bank, National Association (“PNC”), the Company is required to sell the iBio Stock when the trading price of the iBio Stock is less than $0.88 per share for a period of fifteen (15) consecutive trading days on the applicable exchange and utilize all proceeds from such sale to prepay the outstanding principal of the term loan outstanding under the Loan Agreement at such time. During certain periods in the fiscal years ended June 30, 2014 and 2013, the trading price of the iBio Stock was less than $0.88 for a period of fifteen (15) consecutive trading days and continued to have a trading price less than $0.88 during certain periods through April 8, 2015. (See Note 5. Senior Credit Facility, Subordinated Convertible Note, net - CD Financial, LLC and other Long Term Debt).
	As of May 14, 2015, PNC has not required the Company to sell any of the iBio Stock but reserves the right to do so at any time in the future. Although not required to do so, on or about April 30, 2015, the Company sold 60,000 shares of iBio Stock providing net trading proceeds of approximately $64 which were used to prepay principal outstanding under the Term Loan. (See Note 5. Senior Credit Facility, Subordinated Convertible Note, net - CD Financial, LLC and other Long Term Debt).
	Earnings Per Share
	. Basic earnings per common share amounts are based on the weighted average number of common shares outstanding. Diluted earnings per share amounts are based on the weighted average number of common shares outstanding, plus the incremental shares that would have been outstanding upon the assumed exercise of all potentially dilutive stock options, warrants, and convertible debt subject to anti-dilution limitations using the treasury stock method
	The following stock options and potentially dilutive shares for convertible notes payable, were not included in the computation of weighted average diluted common shares outstanding as the effect of doing so would be anti-dilutive for the three and nine months ended March 31, 2015 and 2014:
		Three Months Ended				Nine Months Ended
		March 31,				March 31,
		2015		2014		2015		2014
	Anti-dilutive stock options		829,950		1,782,520		354,200		1,252,770
	Potentially dilutive shares		8,230,769		8,230,769		-		8,230,769
	for convertible notes payable
	Total anti-dilutive shares		9,060,719		10,013,289		354,200		9,483,539

Note_2_Inventories

Note 2 - Inventories	9 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
Inventory Disclosure [Text Block]	Note
	2
	. Inventories
	Inventories are stated at the lower of cost or market using the first-in, first-out method and consist of the following as of:
		March 31,		June 30,
		2015		2014
	Raw materials	$	3,154	$	2,851
	Work-in-process		1,039		1,216
	Finished goods		1,694		1,631
	Total	$	5,887	$	5,698

Note_3_Intangible_Assets_Net

Note 3 - Intangible Assets, Net	9 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	Note 3. Intangible Assets, net
	Intangible assets consist of trade names, license fees from the Branded Proprietary Products Segment, and unpatented technology from the Other Nutraceutical Businesses Segment. The carrying amount of intangible assets, net is as follows as of:
		31-Mar-15						30-Jun-14
		Gross Carrying		Accumulated				Gross Carrying		Accumulated
		Amount		Amortization		Net		Amount		Amortization		Net
	Trade names	$	1,525	$	872	$	653	$	1,525	$	815	$	710
	Unpatented technology		547		530		17		547		500		47
	License agreement		347		240		107		347		224		123
	Total	$	2,419	$	1,642	$	777	$	2,419	$	1,539	$	880
	Amortization expense recorded on intangible assets for each of the three and nine months ended March 31, 2015 and 2014 was $34 and $103, respectively. Amortization expense is recorded on the straight-line basis over periods ranging from 13 years to 20 years based on contractual or estimated lives and is included in selling and administrative expenses. Tests for impairment or recoverability are performed at least annually and require significant management judgment and the use of estimates which the Company believes are reasonable and appropriate at the time of the impairment test. Future unanticipated events affecting cash flows and changes in market conditions could affect such estimates and result in the need for an impairment charge. The Company also re-evaluates the periods of amortization to determine whether circumstances warrant revised estimates of current useful lives. No impairment losses were identified or recorded in the three and nine months ended March 31, 2015 and 2014 on the Company’s intangible assets.
	The estimated annual amortization expense for intangible assets for the five succeeding fiscal years is as follows:
	Year ending	Amortization
	June 30,	Expense
	Remaining in 2015	$	34
	2016		104
	2017		97
	2018		97
	2019		97
	2020		93
	Thereafter		255
	Total	$	777

Note_4_Property_and_Equipment_

Note 4 - Property and Equipment, Net	9 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	Note
	4
	. Property and Equipment, net
	Property and equipment, net consists of the following as of:
		March 31,			June 30,
		2015			2014
	Land and building	$	1,250		$	1,250
	Leasehold improvements		1,151			1,135
	Machinery and equipment		5,367			5,096
	Transportation equipment		17			63
			7,785			7,544
	Less: Accumulated depreciation		(6,354	)		(6,305	)
	and amortization
	Total	$	1,431		$	1,239
	Depreciation and amortization expense recorded on property and equipment was $71 and $60 for the three months ended
	March 31, 2015 and 2014
	, respectively and $202 and $195 for the nine months ended
	March 31, 2015 and 2014
	, respectively. In the nine months ended
	31-Mar-15
	, the Company traded in property and equipment with an original cost of $115 for a cash discount of $6 on the replacement property, resulting in a gain on disposal of $3. In the nine months ended
	31-Mar-14
	, the Company traded in property and equipment with an original cost of $72 for a cash discount of $4 on the replacement property, resulting in a gain on disposal of $4. Additionally, the Company disposed of fully depreciated property of $58 in the nine months ended March 31, 2015.

Note_5_Senior_Credit_Facility_

Note 5 - Senior Credit Facility, Subordinated Convertible Note, Net - CD Financial, LLC and Other Long-Term Debt	9 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
Debt Disclosure [Text Block]	Note
	5
	.
	Senior Credit Facility, Subordinated Convertible Note, net - CD Financial, LLC and other Long Term Debt
	As of March 31, 2015 and June 30, 2014, the Company had the following debt outstanding:
		Principal Amount						Interest			Maturity
								Rate			Date
		As of			As of
		31-Mar-15			30-Jun-14
	Revolving advances under Senior Credit	$	4,412		$	4,121			3.25	%	6/27/17
	Facility with PNC Bank, National Association
	Installment Note with PNC Bank		2,013			2,413			3.75	%	6/27/17
	Line of Credit Note with		307			-			3.43	%	5/31/18
	PNC Equipment Finance
	Promissory Note with CD Financial, LLC		1,714			1,714			6	%	7/7/17
	Promissory Note with Vitamin Realty, LLC		686			686			4	%	7/7/17
	Capitalized lease obligations		161			83			0.00% - 7.10	%	2/28/2015 - 11/20/2016
	Promissory Note with E. Gerald Kay		27			27			4	%	7/7/17
	Promissory Note with Acura Financial Services		-			24			1.9	%	4/15/17
	Total outstanding debt		9,320			9,068
	Less: Revolving Advances		(4,412	)		(4,121	)
	Current portion of long term debt		(828	)		(588	)
	Long term debt	$	4,080		$	4,359
	Convertible Note payable - CD Financial, LLC	$	5,350		$	5,350			6	%	7/7/17
	Discount for embedded derivative		(258	)		(341	)
	Convertible Note payable, net - CD Financial, LLC	$	5,092		$	5,009
	SENIOR CREDIT FACILITY
	On June 27, 2012, the Company, MDC, AgroLabs, IHT, IHT Properties Corp. (“IHT Properties”) and Vitamin Factory (collectively, the “Borrowers”) entered into a Revolving Credit, Term Loan and Security Agreement (the “Loan Agreement”) with PNC Bank, National Association as agent and lender (“PNC”) and the other lenders party thereto.
	The Loan Agreement provides for a total of $11,727 in senior secured financing (the “Senior Credit Facility”) as follows: (i) discretionary advances (“Revolving Advances”) based on eligible accounts receivable and eligible inventory in the maximum amount of $8,000 (the “Revolving Credit Facility”) and (ii) a term loan in the amount of $3,727 (the “Term Loan”). The Senior Credit Facility is secured by all assets of the Borrowers, including, without limitation, machinery and equipment, real estate owned by IHT Properties, and common stock of iBio owned by the Company. Revolving Advances bear interest at PNC’s Base Rate or the Eurodollar Rate, at Borrowers’ option, plus 2.75% (3.25% as of March 31, 2015 and June 30, 2014). The Term Loan bears interest at PNC’s Base Rate or the Eurodollar Rate, at Borrowers’ option, plus 3.25% (3.75% as of March 31, 2015 and June 30, 2014). Upon and after the occurrence of any event of default under the Loan Agreement, and during the continuation thereof, interest shall be payable at the interest rate then applicable plus 2%. The Senior Credit Facility matures on June 27, 2017 (the “Senior Maturity Date”).
	The principal balance of the Revolving Advances is payable on the Senior Maturity Date, subject to acceleration, based upon a material adverse event clause, as defined, subjective accelerations for borrowing base reserves, as defined or upon the occurrence of any event of default under the Loan Agreement or earlier termination of the Loan Agreement pursuant to the terms thereof. The Term Loan shall be repaid in sixty (60) consecutive monthly installments of principal, the first fifty nine (59) of which shall be in the amount of $44, commencing on the first business day of August, 2012, and continuing on the first business day of each month thereafter, with a final payment of any unpaid balance of principal and interest payable on the first business day of July, 2017. The foregoing is subject to customary mandatory prepayment provisions and acceleration upon the occurrence of any event of default under the Loan Agreement or earlier termination of the Loan Agreement pursuant to the terms thereof.
	The Revolving Advances are subject to the terms and conditions set forth in the Loan Agreement and are made in aggregate amounts at any time equal to the lesser of (x) $8.0 million or (y) an amount equal to the sum of: (i) up to 85%, subject to the provisions in the Loan Agreement, of eligible accounts receivables (“Receivables Advance Rate”), plus (ii) up to the lesser of (A) 65%, subject to the provisions in the Loan Agreement, of the value of the eligible inventory (“Inventory Advance Rate” and together with the Receivables Advance Rate, collectively, the “Advance Rates”), (B) 85% of the appraised net orderly liquidation value of eligible inventory (as evidenced by the most recent inventory appraisal reasonably satisfactory to PNC in its sole discretion exercised in good faith) and (C) the inventory sublimit in the aggregate at any one time (“Inventory Advance Rate” and together with the Receivables Advance Rate, collectively, the “Advance Rates”), minus (iii) the aggregate Maximum Undrawn Amount of all outstanding Letters of Credit, minus (iv) such reserves as Agent may reasonably deem proper and necessary from time to time.
	The Loan Agreement contains customary mandatory prepayment provisions, including, without limitation, (i) the requirement that if the trading price per share of the iBio Stock falls below a certain amount, the Company must sell the iBio Stock and use the proceeds to repay the Term Loan and (ii) the requirement to prepay the outstanding amount of all loans in an amount equal to fifty percent (50%) of Excess Cash Flow for each fiscal year commencing with the fiscal year ending June 30, 2013, payable upon delivery of the financial statements to PNC referred to in and required by the Loan Agreement for such fiscal year but in any event not later than one hundred twenty (120) days after the end of each such fiscal year, which prepayment amount shall be applied ratably to the outstanding principal installments of the Term Loan in the inverse order of the maturities thereof until the aggregate amount of payments made with regard to the Term Loan pursuant to Loan Agreement equals $1.0 million. The Loan Agreement also contains customary representations and warranties, covenants and events of default, including, without limitation, (i) a fixed charge coverage ratio maintenance requirement and (ii) an event of default tied to any change of control as defined in the Loan Agreement. As of March 31, 2015, the Company was in compliance with the fixed charge coverage ratio maintenance requirement.
	During certain periods in the fiscal years ended June 30, 2014 and 2013, the trading price of the iBio Stock was less than $0.88 for a period of fifteen (15) consecutive trading days and continued to have a trading price less than $0.88 during certain periods through April 8, 2015. However, PNC temporarily waived the requirement to sell the iBio Stock due to certain trading rules and restrictions under Rule 144 under the Securities Act of 1933, as amended. As of May 14, 2015, PNC has not required the Company to sell any of the iBio Stock but reserves the right to do so at any time in the future. Although not required to do so, on or about April 30, 2015, the Company sold 60,000 shares of iBio Stock, providing net trading proceeds of approximately $64 which proceeds were used to prepay principal outstanding under the Term Loan.
	In October, 2013, when the Company delivered its annual financial statements for the fiscal year ended June 30, 2013 to PNC, as required under the Loan Agreement, the Company was required to make a prepayment in respect of loans outstanding under the Loan Agreement of approximately $293, representing 50% of Excess Cash Flows for the fiscal year ended June 30, 2013. This payment, along with the scheduled monthly principal payments of $44 made by the Company in respect of the Term Loan through November 1, 2013 provided for principal payments of $1.0 million in the aggregate.
	In connection with the Senior Credit Facility, each of E. Gerald Kay, an officer, director and major stockholder of the Company, and Carl DeSantis, a director and major stockholder of the Company and a member of CD Financial, LLC(“CD Financial”) (collectively, the “Guarantors”), entered into Continuing Limited Guarantees (collectively, the “Individual Guarantees”) with PNC whereby each Guarantor irrevocably and unconditionally guarantees the full, prompt and unconditional payment, when due, whether by acceleration or otherwise, of any and all obligations of the Borrowers under the Loan Agreement and the other loan documents. The liability of each Guarantor under his respective Individual Guarantee is limited to a maximum of $1.0 million. The Individual Guarantees automatically terminate upon the satisfaction of certain conditions set forth in the Loan Agreement. These conditions included the Company repaying an aggregate amount of $1.0 million of principal on the Term Loan and the Company meeting a minimum EBITDA, as defined in the Loan Agreement, of $1.5 million for the fiscal year ended June 30, 2013. The Company met these requirements on November 1, 2013 and Mr. DeSantis and Mr. Kay were released as guarantors under the Individual Guarantees.
	Also, in connection with the Senior Credit Facility, PNC and CD Financial entered into the Intercreditor and Subordination Agreement (the “Intercreditor Agreement”), which was acknowledged by the Borrowers, pursuant to which, among other things, (a) the lien of CD Financial on assets of the Borrowers is subordinated to the lien of PNC on such assets during the effectiveness of the Senior Credit Facility, and (b) priorities for payment of the debt for the Company and its subsidiaries (as described in this Note 5) are established.
	In addition, in connection with the Senior Credit Facility, the following loan documents were executed: (i) a Stock Pledge Agreement with PNC, pursuant to which the Company pledged to PNC the iBio Stock; (ii) a Mortgage and Security Agreement with PNC with IHT Properties; and (iii) an Environmental Indemnity Agreement with PNC.
	CD FINANCIAL, LLC
	TROUBLED DEBT RESTRUCTURING
	On June 27, 2012, the Company also entered into an Amended and Restated Securities Purchase Agreement (the “CD SPA”) with CD Financial, which amended and restated the Securities Purchase Agreement, dated as of February 21, 2008, between the Company and CD Financial, pursuant to which the Company issued to CD Financial a 9.5% Convertible Senior Secured Note in the original principal amount of $4,500 (the “Original CD Note”). Pursuant to the CD SPA, the Company issued to CD Financial (i) the Amended and Restated Convertible Promissory Note in the principal amount of $5,350 (the “CD Convertible Note”) and (ii) the Promissory Note in the principal amount of $1,714 (the “Liquidity Note”, and collectively with the CD Convertible Note, the “CD Notes”). The CD Notes mature on July 7, 2017.
	The proceeds of the CD Notes were used to refinance (a) the Original CD Note, (b) a $300,000 note issued by MDC to CD Financial which was assigned by MDC to the Company, (c) past due interest in the aggregate amount of $333 and (d) other expenses owed to CD Financial by the Company in the aggregate amount of approximately $217.
	The CD Notes are secured by all assets of the Borrowers, including, without limitation, machinery and equipment, real estate owned by IHT Properties, and iBio Stock owned by the Company. The CD Notes bear interest at an annual rate of 6% and have a default rate of 10%.
	The CD Convertible Note is convertible at the option of CD Financial into common stock of the Company at a conversion price of $0.65 per share, subject to customary adjustments including conversion price protection provisions.
	Pursuant to the terms of the Loan Agreement and the Intercreditor Agreement, during the effectiveness of the Senior Credit Facility, (i) the principal of the CD Convertible Note may not be repaid, (ii) the principal of the Liquidity Note may only be repaid if certain conditions under the Loan Agreement are satisfied, and (iii) interest in respect of the CD Notes may only be paid if certain conditions under the Intercreditor Agreement are satisfied.
	The CD SPA contains customary representations and warranties, covenants and events of default, including, without limitation, an event of default tied to any change of control as defined in the CD SPA.
	In connection with the CD SPA, the Borrowers entered into an Amended and Restated Security Agreement and Amended and Restated Subsidiary Guaranty.
	As of March 31, 2015 and June 30, 2014, the related embedded derivative liability with respect to conversion price protection provisions on the CD Convertible Note has an estimated fair value of $15 and $717, respectively.
	The Company used the following assumptions to calculate the fair value of the derivative liability using the Black-Scholes option pricing model:
		March 31,			June 30,			June 27,
		2015			2014			2012
	Risk Free Interest Rate		0.6	%		0.88	%		0.72	%
	Volatility		69.7	%		88.5	%		144.1	%
	Term (in years)		2.25			3			5
	Dividend Rate		0	%		0	%		0	%
	Closing Price of
	Common Stock	$	0.08		$	0.25		$	0.09
	OTHER LONG TERM DEBT
	Related Party Debt
	.
	On June 27, 2012, MDC and the Company entered into separate promissory notes with (i) Vitamin Realty Associates, LLC (“Vitamin Realty”), which is 100% owned by E. Gerald Kay, the Company’s Chairman of the Board, President and major shareholder and certain of his family members, who are also executive officers and directors of the Company, and (ii) E. Gerald Kay, in the principal amounts of approximately $686 (the “Vitamin Note”) and $27 (the “Kay Note”), respectively (collectively the “Related Party Notes”). The principal amount of the Vitamin Note represents the aggregate amount of unpaid, past due rent owing by MDC under the Lease Agreement, dated as of January 10, 1997, between MDC, as lessor, and Vitamin Realty, as landlord, pertaining to the real property located at 225 Long Avenue, Hillside, New Jersey. (See Note 7. Commitments and Contingencies (a) Leases – Related Party Leases). The Kay Note represents amounts owed to Mr. Kay for unreimbursed business expenses incurred by Mr. Kay in the fiscal year ended June 30, 2008. The Related Party Notes mature on July 7, 2017 and accrue interest at an annual rate of 4% per annum. Interest in respect of the Related Party Notes is payable on the first business day of each calendar month. Pursuant to the terms of the Loan Agreement, during the effectiveness of the Senior Credit Facility, the Related Party Notes may only be repaid or prepaid if certain conditions set forth in the Loan Agreement are satisfied.
	Other Note Payable.
	On February 23, 2015, the Company satisfied the outstanding balance of approximately $19 with Acura Financial Services, Inc, (“Acura”), originally entered into on March 31, 2012 in the amount of $41, under a trade in with Acura for a new auto vehicle with an operating lease with Acura. The loan was secured by an automobile and was set to mature on April 15, 2017. Interest and principal in the original amount of less than $1 was payable monthly and had an interest rate of 1.9%.
	Capitalized Lease Obligations.
	On August 22, 2014,
the Company entered into a capitalized lease obligation with Marlin Leasing in the amount of $47, which lease is secured by certain machinery and equipment and matures on August 28, 2016. The lease payment amount of approximately $2 is payable monthly and has an imputed interest rate of 5.6%.
On August 28, 2014, the Company entered into a capitalized lease obligation with Quantum Analytics in the amount of $138, which lease is secured by certain machinery and equipment and matures on February 27, 2016. The lease payment amount of approximately $8 is payable monthly and has an imputed interest rate of 0%.
On February 28, 2015, the capitalized lease obligation the Company entered into on March 5, 2013 with Marlin Leasing in the amount of $68, which lease was secured by certain machinery and equipment, was satisfied with all payments being made under the capitalized lease obligation. The monthly lease payment amount was approximately $2 and had an imputed interest rate of 7.1%.
Equipment Financing Not
e.
On September 22, 2014, MDC entered into a Convertible Line of Credit Note (the “LC Note”) in the amount of $350 with PNC Equipment Finance, LLC (“PNCEF”). The LC Note is convertible into a term note upon completion of the advances under the LC Note. During the period from September 22, 2014 to and including the Conversion Date (defined below), the Company may borrow up to the full value of the LC Note ($350). The “Conversion Date” is the earliest to occur of (i) July 31, 2015 or (ii) the date when the Company notifies PNCEF that no more advances will be requested or (iii) the date when PNCEF has made advances in an aggregate amount of $350. As of March 31, 2015, the Company has requested and received advances under the LC Note in the amount of $307. Prior to the Conversion Date, amounts outstanding under the LC Note bear interest at a rate per annum (“Floating Rate”) which is at all times equal to the sum of LIBOR Rate plus 325 basis points (3.25%). As of March 31, 2015, the Floating Rate was approximately 3.43%. The Company is expecting to complete the advances no later than the fiscal quarter ending June 30, 2015 and convert the LC Note to a three year term note, at which time the Company will have the option to elect a fixed rate of interest as offered by PNCEF on the Conversion Date.
In addition, in connection with the LC Note, the following loan documents were executed: (i) a Security Agreement with PNCEF and MDC; (ii) a Guaranty and Security Agreement with PNCEF and the Company; and (iii) a Cross Collateralization Agreement with PNC, PNCEF and MDC.

Note_6_Significant_Risks_and_U

Note 6 - Significant Risks and Uncertainties	9 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	Note 6. Significant Risks and Uncertainties
	(a) Major Customers.
	For the three months ended March 31, 2015 and 2014, approximately 83% and 78%, respectively of consolidated net sales, were derived from two customers. These two customers are in the Company’s Contract Manufacturing Segment and represent approximately 37% and 56% and 58% and 30% of this Segment’s net sales in the three months ended March 31, 2015 and 2014, respectively.
	A third customer in the Branded Nutraceutical Segment, while not a significant customer of the Company’s consolidated net sales, represented approximately 82% and 15% of net sales in the three months ended March 31, 2015 and 2014, respectively, of the Branded Nutraceutical Segment.
	For the nine months ended March 31, 2015 and 2014, approximately 83% and 80%, respectively of consolidated net sales, were derived from the same two customers. These two customers are in the Company’s Contract Manufacturing Segment and represent approximately 48% and 42% and 68% and 21% of this Segment’s net sales in the nine months ended March 31, 2015 and 2014, respectively. A third customer in the Branded Nutraceutical Segment, while not a significant customer of the Company’s consolidated net sales, represented approximately 79% and 52% of net sales in the nine months ended March 31, 2015 and 2014, respectively, of the Branded Nutraceutical Segment.
	Accounts receivable from major customers represented approximately 80% and 74% of total net accounts receivable as of March 31, 2015 and June 30, 2014, respectively. The loss of any of these customers could have an adverse affect on the Company’s operations. Major customers are those customers who account for more than 10% of net sales.
	(b) Other Business Risks.
	Approximately 62% of the Company’s employees are covered by a union contract and are employed in its New Jersey facilities. The contract was renewed in May 2012 and expires in August 2015.

Note_7_Commitments_and_Conting

Note 7 - Commitments and Contingencies	9 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 7. Commitments and Contingencies
	(a) Leases
	Related Party Leases.
	Warehouse and office facilities are leased from Vitamin Realty, which is 100% owned by the Company’s chairman, president and major stockholder and certain of his family members, who are also executive officers and directors of the Company. On January 5, 2012, MDC, a wholly-owned subsidiary of the Company, entered into a second amendment of lease (the “Second Lease Amendment”) with Vitamin Realty for its office and warehouse space in New Jersey increasing its rentable square footage from an aggregate of 74,898 square feet to 76,161 square feet and extending the expiration date to January 31, 2026. This Second Lease Amendment provides for minimum annual rental payments of $533, plus increases in real estate taxes and building operating expenses. On May 19, 2014, AgroLabs entered into an Amendment to the lease agreement entered into on January 5, 2012, with Vitamin Realty for an additional 2,700 square feet of warehouse space in New Jersey, the term of which was to expire on January 31, 2019 to extend the expiration date to January 1, 2024. This additional lease provides for minimum lease payments of $27 with annual increases plus the proportionate share of operating expenses.
	Rent expense for the three and nine months ended March 31, 2015 and 2014 on these leases were $223 and $215 and $637 and $622, respectively, and are included in both cost of sales and selling and administrative expenses in the accompanying Condensed Consolidated Statements of Operations. As of March 31, 2015 and June 30, 2014, the Company had an outstanding obligation to Vitamin Realty of $947 and $902, respectively, included in accounts payable, accrued expenses and other liabilities and long term debt in the accompanying Condensed Consolidated Balance Sheet.
	Other Lease Commitments.
	The Company has entered into certain non-cancelable operating lease agreements expiring up through January 31, 2026, related to office and warehouse space, equipment and vehicles (inclusive of the related party lease with Vitamin Realty).
	The minimum rental and lease commitments for long-term non-cancelable leases are as follows:
		Operating		Related Party
	Year ending	Lease		Lease
	June 30,	Commitment		Commitment		Total
	2015, remaining	$	14	$	141	$	155
	2016		47		563		610
	2017		25		563		588
	2018		14		563		577
	2019		2		563		565
	2020		1		563		564
	Thereafter		-		3,080		3,080
	Total	$	103	$	6,036	$	6,139
	Total rent expense, including real estate taxes and maintenance charges, was approximately $262 and $258 and $759 and $749 for the three and nine months ended March 31, 2015 and 2014, respectively. Rent expense is included in cost of sales and selling and administrative expenses in the accompanying Condensed Consolidated Statements of Operations.
	(b) Legal Proceedings.
	The Company is subject, from time to time, to claims by third parties under various legal theories. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company’s liquidity, financial condition and cash flows.
	(c) Other Claims.
	On May 15, 2012, Cedarburg Pharmaceuticals, Inc. ("Cedarburg") sent the Company a letter (the "Demand Letter") setting forth a demand for indemnification under the Stock Purchase Agreement, dated March 17, 2009 (the "Cedarburg SPA"), by and among Cedarburg, InB: Hauser Pharmaceutical Services, Inc., InB: Paxis Pharmaceuticals, Inc. and the Company. In the Demand Letter, Cedarburg demanded payment by the Company of $0.6 million in respect of the Company's indemnification obligations under the Cedarburg SPA. In addition, in the Demand Letter, Cedarburg informed the Company that there are also environmental issues pending which may lead to additional costs to Cedarburg which will likely be in excess of $0.3 million.
	On May 30, 2012, the Company sent a letter responding to the Demand Letter and setting forth the Company’s position that it has no obligation to indemnify Cedarburg as demanded. On June 18, 2012, Cedarburg responded to the Company’s letter and, on July 27, 2012, the Company sent another letter to Cedarburg reiterating its position that the Company has no obligation to indemnify Cedarburg as demanded. On December 18, 2012, Cedarburg responded to the Company’s letter and, on January 15, 2013, the Company sent another letter to Cedarburg reiterating its position that the Company has no obligation to indemnify Cedarburg as demanded. As of May 14, 2015, the Company has not received any further communication from Cedarburg with respect to its demand for indemnification as set forth in the Demand Letter. The Company intends to vigorously contest Cedarburg's demand as set forth in the Demand Letter.

Note_8_Related_Party_Transacti

Note 8 - Related Party Transactions	9 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 8. Related Party Transactions
	On June 27, 2012, Carl DeSantis, a director and major shareholder of the Company and a member of CD Financial and E. Gerald Kay, the Company’s Chief Executive Officer, Chairman of the Board, President and a major shareholder each entered into Limited Guaranty Agreements with PNC in the amount of $1.0 million each. (See Note 5. Senior Credit Facility, Subordinated Convertible Note, net - CD Financial, LLC and other Long Term Debt).
	Neither Mr. DeSantis nor Mr. Kay received any compensation from the Company in connection with these guarantees. The Individual Guarantees automatically terminated upon the satisfaction of certain conditions set forth in the Loan Agreement which included the Company repaying an aggregate amount of $1.0 million of principal on the Term Loan and the Company meeting a minimum EBITDA, as defined in the Loan Agreement, of $1.5 million for the fiscal year ended June 30, 2013. These two conditions were met by the Company on November 1, 2013 and Mr. DeSantis and Mr. Kay were released as guarantors under the Individual Guarantees.
	See Note 5. Senior Credit Facility, Subordinated Convertible Note, net - CD Financial, LLC and other Long Term Debt for related party securities transactions.
	See Note 7. Commitments and Contingencies (a) Leases – Related Party Leases.

Note_9_Segment_Information

Note 9 - Segment Information	9 Months Ended
	Mar. 31, 2015
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	Note 9. Segment Information
	The basis for presenting segment results generally is consistent with overall Company reporting. The Company reports information about its operating segments in accordance with GAAP which establishes standards for reporting information about a company’s operating segments.
	The Company has divided its operations into three reportable segments as follows: Contract Manufacturing, Branded Proprietary Products and Other Nutraceutical Businesses. The international sales, concentrated primarily in Europe and Canada, for the three months ended March 31, 2015 and 2014 were $2,174 and $2,113, respectively and for the nine months ended March 31, 2015 and 2014 were $6,570 and $8,369, respectively.
	Financial information relating to the three months ended March 31, 2015 and 2014 operations by business segment are as follows:
				Sales, Net							Segment
				U.S.			International				Gross					Capital
				Customers			Customers		Total		Profit (Loss)			Depreciation		Expenditures
	Contract Manufacturing	2015		$	6,893		$	1,805	$	8,698	$	681		$	70	$	39
		2014			4,713			2,058		6,771		643			57		86
	Branded Proprietary Products	2015			82			300		382		(5	)		-		-
		2014			147			45		192		(64	)		1		-
	Other Nutraceutical Businesses	2015			522			69		591		223			1		-
		2014			549			10		559		148			2		-
	Total Company	2015			7,497			2,174		9,671		899			71		39
		2014			5,409			2,113		7,522		727			60		86
	Financial information relating to the nine months ended March 31, 2015 and 2014 operations by business segment are as follows:
				Sales, Net							Segment
				U.S.			International				Gross					Capital
				Customers			Customers		Total		Profit (Loss)			Depreciation		Expenditures
	Contract Manufacturing	2015		$	20,272		$	5,876	$	26,148	$	2,965		$	200	$	412
		2014			15,115			7,739		22,854		3,217			185		166
	Branded Proprietary Products	2015			280			586		866		(74	)		1		1
		2014			409			527		936		100			2		-
	Other Nutraceutical Businesses	2015			1,422			108		1,530		565			1		-
		2014			1,608			103		1,711		476			8		2
	Total Company	2015			21,974			6,570		28,544		3,456			202		413
		2014			17,132			8,369		25,501		3,793			195		168
			Total Assets as of
			March 31,			June 30,
			2015			2014
	Contract Manufacturing		$	9,021		$	7,752
	Branded Proprietary Products			1,441			1,781
	Other Nutraceutical Businesses			1,958			2,050
	Total Company		$	12,420		$	11,583

Significant_Accounting_Policie

Significant Accounting Policies (Policies)	9 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Equity Method Investments, Policy [Policy Text Block]	Investment in iBio, Inc
	.
	The Company accounts for its investment in iBio, Inc. (“iBio”) common stock on the cost basis as it initially retained approximately 6% of its interest in iBio (1,266,706 common shares) (the “iBio Stock”) at the time of the spin-off of this subsidiary in August 2008.  The Company reviews its investment in iBio for impairment and records a loss when there is deemed to be an impairment of the investment. To date, there were cumulative impairment charges of $298. The market value of the iBio Stock as of March 31, 2015 was approximately $1.0 million.
	Pursuant to the Company’s Loan Agreement with PNC Bank, National Association (“PNC”), the Company is required to sell the iBio Stock when the trading price of the iBio Stock is less than $0.88 per share for a period of fifteen (15) consecutive trading days on the applicable exchange and utilize all proceeds from such sale to prepay the outstanding principal of the term loan outstanding under the Loan Agreement at such time. During certain periods in the fiscal years ended June 30, 2014 and 2013, the trading price of the iBio Stock was less than $0.88 for a period of fifteen (15) consecutive trading days and continued to have a trading price less than $0.88 during certain periods through April 8, 2015. (See Note 5. Senior Credit Facility, Subordinated Convertible Note, net - CD Financial, LLC and other Long Term Debt).
	As of May 14, 2015, PNC has not required the Company to sell any of the iBio Stock but reserves the right to do so at any time in the future. Although not required to do so, on or about April 30, 2015, the Company sold 60,000 shares of iBio Stock providing net trading proceeds of approximately $64 which were used to prepay principal outstanding under the Term Loan. (See Note 5. Senior Credit Facility, Subordinated Convertible Note, net - CD Financial, LLC and other Long Term Debt).
Earnings Per Share, Policy [Policy Text Block]	Earnings Per Share
	. Basic earnings per common share amounts are based on the weighted average number of common shares outstanding. Diluted earnings per share amounts are based on the weighted average number of common shares outstanding, plus the incremental shares that would have been outstanding upon the assumed exercise of all potentially dilutive stock options, warrants, and convertible debt subject to anti-dilution limitations using the treasury stock method
	The following stock options and potentially dilutive shares for convertible notes payable, were not included in the computation of weighted average diluted common shares outstanding as the effect of doing so would be anti-dilutive for the three and nine months ended March 31, 2015 and 2014:
		Three Months Ended				Nine Months Ended
		March 31,				March 31,
		2015		2014		2015		2014
	Anti-dilutive stock options		829,950		1,782,520		354,200		1,252,770
	Potentially dilutive shares		8,230,769		8,230,769		-		8,230,769
	for convertible notes payable
	Total anti-dilutive shares		9,060,719		10,013,289		354,200		9,483,539

Note_1_Principles_of_Consolida1

Note 1 - Principles of Consolidation and Basis of Presentation (Tables)	9 Months Ended
	Mar. 31, 2015
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]		Three Months Ended				Nine Months Ended
		March 31,				March 31,
		2015		2014		2015		2014
	Anti-dilutive stock options		829,950		1,782,520		354,200		1,252,770
	Potentially dilutive shares		8,230,769		8,230,769		-		8,230,769
	for convertible notes payable
	Total anti-dilutive shares		9,060,719		10,013,289		354,200		9,483,539

Note_2_Inventories_Tables

Note 2 - Inventories (Tables)	9 Months Ended
	Mar. 31, 2015
Notes Tables
Schedule of Inventory, Current [Table Text Block]		March 31,		June 30,
		2015		2014
	Raw materials	$	3,154	$	2,851
	Work-in-process		1,039		1,216
	Finished goods		1,694		1,631
	Total	$	5,887	$	5,698

Note_3_Intangible_Assets_Net_T

Note 3 - Intangible Assets, Net (Tables)	9 Months Ended
	Mar. 31, 2015
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]		31-Mar-15						30-Jun-14
		Gross Carrying		Accumulated				Gross Carrying		Accumulated
		Amount		Amortization		Net		Amount		Amortization		Net
	Trade names	$	1,525	$	872	$	653	$	1,525	$	815	$	710
	Unpatented technology		547		530		17		547		500		47
	License agreement		347		240		107		347		224		123
	Total	$	2,419	$	1,642	$	777	$	2,419	$	1,539	$	880
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Year ending	Amortization
	June 30,	Expense
	Remaining in 2015	$	34
	2016		104
	2017		97
	2018		97
	2019		97
	2020		93
	Thereafter		255
	Total	$	777

Note_4_Property_and_Equipment_1

Note 4 - Property and Equipment, Net (Tables)	9 Months Ended
	Mar. 31, 2015
Notes Tables
Property, Plant and Equipment [Table Text Block]		March 31,			June 30,
		2015			2014
	Land and building	$	1,250		$	1,250
	Leasehold improvements		1,151			1,135
	Machinery and equipment		5,367			5,096
	Transportation equipment		17			63
			7,785			7,544
	Less: Accumulated depreciation		(6,354	)		(6,305	)
	and amortization
	Total	$	1,431		$	1,239

Note_5_Senior_Credit_Facility_1

Note 5 - Senior Credit Facility, Subordinated Convertible Note, Net - CD Financial, LLC and Other Long-Term Debt (Tables)	9 Months Ended
	Mar. 31, 2015
Notes Tables
Schedule of Debt [Table Text Block]		Principal Amount						Interest			Maturity
								Rate			Date
		As of			As of
		31-Mar-15			30-Jun-14
	Revolving advances under Senior Credit	$	4,412		$	4,121			3.25	%	6/27/17
	Facility with PNC Bank, National Association
	Installment Note with PNC Bank		2,013			2,413			3.75	%	6/27/17
	Line of Credit Note with		307			-			3.43	%	5/31/18
	PNC Equipment Finance
	Promissory Note with CD Financial, LLC		1,714			1,714			6	%	7/7/17
	Promissory Note with Vitamin Realty, LLC		686			686			4	%	7/7/17
	Capitalized lease obligations		161			83			0.00% - 7.10	%	2/28/2015 - 11/20/2016
	Promissory Note with E. Gerald Kay		27			27			4	%	7/7/17
	Promissory Note with Acura Financial Services		-			24			1.9	%	4/15/17
	Total outstanding debt		9,320			9,068
	Less: Revolving Advances		(4,412	)		(4,121	)
	Current portion of long term debt		(828	)		(588	)
	Long term debt	$	4,080		$	4,359
	Convertible Note payable - CD Financial, LLC	$	5,350		$	5,350			6	%	7/7/17
	Discount for embedded derivative		(258	)		(341	)
	Convertible Note payable, net - CD Financial, LLC	$	5,092		$	5,009
Schedule of Derivative Liabilities at Fair Value [Table Text Block]		March 31,			June 30,			June 27,
		2015			2014			2012
	Risk Free Interest Rate		0.6	%		0.88	%		0.72	%
	Volatility		69.7	%		88.5	%		144.1	%
	Term (in years)		2.25			3			5
	Dividend Rate		0	%		0	%		0	%
	Closing Price of
	Common Stock	$	0.08		$	0.25		$	0.09

Note_7_Commitments_and_Conting1

Note 7 - Commitments and Contingencies (Tables)	9 Months Ended
	Mar. 31, 2015
Notes Tables
Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]		Operating		Related Party
	Year ending	Lease		Lease
	June 30,	Commitment		Commitment		Total
	2015, remaining	$	14	$	141	$	155
	2016		47		563		610
	2017		25		563		588
	2018		14		563		577
	2019		2		563		565
	2020		1		563		564
	Thereafter		-		3,080		3,080
	Total	$	103	$	6,036	$	6,139

Note_9_Segment_Information_Tab

Note 9 - Segment Information (Tables)	9 Months Ended
	Mar. 31, 2015
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]				Sales, Net							Segment
				U.S.			International				Gross					Capital
				Customers			Customers		Total		Profit (Loss)			Depreciation		Expenditures
	Contract Manufacturing	2015		$	6,893		$	1,805	$	8,698	$	681		$	70	$	39
		2014			4,713			2,058		6,771		643			57		86
	Branded Proprietary Products	2015			82			300		382		(5	)		-		-
		2014			147			45		192		(64	)		1		-
	Other Nutraceutical Businesses	2015			522			69		591		223			1		-
		2014			549			10		559		148			2		-
	Total Company	2015			7,497			2,174		9,671		899			71		39
		2014			5,409			2,113		7,522		727			60		86
				Sales, Net							Segment
				U.S.			International				Gross					Capital
				Customers			Customers		Total		Profit (Loss)			Depreciation		Expenditures
	Contract Manufacturing	2015		$	20,272		$	5,876	$	26,148	$	2,965		$	200	$	412
		2014			15,115			7,739		22,854		3,217			185		166
	Branded Proprietary Products	2015			280			586		866		(74	)		1		1
		2014			409			527		936		100			2		-
	Other Nutraceutical Businesses	2015			1,422			108		1,530		565			1		-
		2014			1,608			103		1,711		476			8		2
	Total Company	2015			21,974			6,570		28,544		3,456			202		413
		2014			17,132			8,369		25,501		3,793			195		168
Reconciliation of Assets from Segment to Consolidated [Table Text Block]			Total Assets as of
			March 31,			June 30,
			2015			2014
	Contract Manufacturing		$	9,021		$	7,752
	Branded Proprietary Products			1,441			1,781
	Other Nutraceutical Businesses			1,958			2,050
	Total Company		$	12,420		$	11,583

Note_1_Principles_of_Consolida2

Note 1 - Principles of Consolidation and Basis of Presentation (Details Textual) (USD $)	9 Months Ended	0 Months Ended	4 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	15-May-15	15-May-15	Jun. 30, 2014	Jun. 27, 2012
Share Price	$0.08			$0.25	$0.09
IBio Inc [Member] | Minimum Share Price Acceptable Before Required to Sell [Member]
Share Price	$0.88
IBio Inc [Member]
Equity Method Investment, Ownership Percentage	6.00%
Investment Owned, Balance, Shares	1,266,706
Asset Impairment Charges	$298
Investment Owned, at Fair Value	1,000
Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues		60,000	60,000
Stock Issued During Period, Value, New Issues		$64	$64

Note_1_Principles_of_Consolida3

Note 1 - Principles of Consolidation and Basis of Presentation - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)	3 Months Ended		9 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Anti-dilutive shares (in shares)	9,060,719	10,013,289	354,200	9,483,539
Equity Option [Member]
Anti-dilutive shares (in shares)	829,950	1,782,520	354,200	1,252,770
Convertible Debt Securities [Member]
Anti-dilutive shares (in shares)	8,230,769	8,230,769		8,230,769

Note_2_Inventories_Inventory_D

Note 2 - Inventories - Inventory (Details) (USD $)	Mar. 31, 2015	Jun. 30, 2014
In Thousands, unless otherwise specified
Raw materials	$3,154	$2,851
Work-in-process	1,039	1,216
Finished goods	1,694	1,631
Total	$5,887	$5,698

Note_3_Intangible_Assets_Net_D

Note 3 - Intangible Assets, Net (Details Textual) (USD $)	3 Months Ended	9 Months Ended	15 Months Ended	21 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2015	Mar. 31, 2015	Mar. 31, 2015
Amortization of Intangible Assets	$34	$103	$34	$103
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life		13 years
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life		20 years

Note_3_Intangible_Assets_Net_F

Note 3 - Intangible Assets, Net - Finite-lived Intangible Assets (Details) (USD $)	Mar. 31, 2015	Jun. 30, 2014
In Thousands, unless otherwise specified
Gross Carrying Amount	$2,419	$2,419
Accumulated Amortization	1,642	1,539
Intangible assets, net	777	880
Trade Names [Member]
Gross Carrying Amount	1,525	1,525
Accumulated Amortization	872	815
Intangible assets, net	653	710
Unpatented Technology [Member]
Gross Carrying Amount	547	547
Accumulated Amortization	530	500
Intangible assets, net	17	47
Licensing Agreements [Member]
Gross Carrying Amount	347	347
Accumulated Amortization	240	224
Intangible assets, net	$107	$123

Note_3_Intangible_Assets_Net_E

Note 3 - Intangible Assets, Net - Estimated Annual Amortization Expense for Intangible Assets (Details) (USD $)	Mar. 31, 2015
In Thousands, unless otherwise specified
Remaining in 2015	$34
2016	104
2017	97
2018	97
2019	97
2020	93
Thereafter	255
Total	$777

Note_4_Property_and_Equipment_2

Note 4 - Property and Equipment, Net (Details Textual) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Depreciation	$71	$60	$202	$195
Property, Plant and Equipment, Disposals			115	72
Cash Discount on Property			6	4
Gain (Loss) on Disposition of Assets			3	4
Proceeds from Sale of Property, Plant, and Equipment			$58

Note_4_Property_and_Equipment_3

Note 4 - Property and Equipment, Net - Property and Equipment, Net (Details) (USD $)	Mar. 31, 2015	Jun. 30, 2014
In Thousands, unless otherwise specified
Property and equipment, gross	$7,785	$7,544
Less: Accumulated depreciation and amortization	-6,354	-6,305
Total	1,431	1,239
Land and Building [Member]
Property and equipment, gross	1,250	1,250
Leasehold Improvements [Member]
Property and equipment, gross	1,151	1,135
Machinery and Equipment [Member]
Property and equipment, gross	5,367	5,096
Transportation Equipment [Member]
Property and equipment, gross	$17	$63

Note_5_Senior_Credit_Facility_2

Note 5 - Senior Credit Facility, Subordinated Convertible Note, Net - CD Financial, LLC and Other Long-Term Debt (Details Textual) (USD $)	1 Months Ended	9 Months Ended		12 Months Ended	1 Months Ended		0 Months Ended	4 Months Ended	1 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 27, 2012	Mar. 31, 2015	Mar. 31, 2014	Jun. 30, 2013	Mar. 31, 2015	Sep. 22, 2014	15-May-15	15-May-15	Feb. 28, 2015	Aug. 22, 2014	Aug. 28, 2014	Jun. 30, 2014	Oct. 31, 2013	Feb. 23, 2015	Mar. 31, 2012	Feb. 21, 2008	Sep. 30, 2014
Senior Notes	$11,727
Loans Payable, Noncurrent	3,727
Debt Instrument, Periodic Payment		44
Share Price	$0.09	$0.08			$0.08							$0.25
Guarantor Obligations, Maximum Exposure, Undiscounted													1,000
Minimum EBITDA				1,500
Repayments of Notes Payable		404	699
Interest Paid	333	539	537
Other Expenses	217
Capital Lease Obligations		161			161							83
Term Loan [Member] | Eurodollar [Member]
Line of Credit Facility, Interest Rate at Period End												3.75%
Debt Instrument, Basis Spread on Variable Rate		3.25%
Term Loan [Member] | Scenario Event of Default [Member]
Debt Instrument, Interest Rate, Increase (Decrease)		2.00%
Term Loan [Member]
Line of Credit Facility, Interest Rate at Period End		3.75%			3.75%
Repayments of Debt				1,000
Revolving Advances [Member]
Line of Credit Facility Covenant Maximum Aggregate Revolving Advance		8,000			8,000
Line of Credit Facility Covenant Aggregate Revolving Advance Receivables Advance Rate		85.00%			85.00%
Line of Credit Facility Covenant Aggregate Revolving Advance Inventory Advance Rate		65.00%			65.00%
Line of Credit Facility Covenant Prepayment Provisions Percentage of Excess Cash flow		50.00%			50.00%
Loan Agreement Mandatory Repayment Amount		1,000			1,000
Promissory Note [Member] | CD Financial LLC [Member]
Debt Instrument, Face Amount	1,714
CD MDC Note [Member]
Repayments of Notes Payable	300,000
E. Gerald Kay [Member] | Vitamin Realty LLC [Member]
Debt Instrument, Interest Rate, Stated Percentage		4.00%			4.00%
Acura Financial Services [Member]
Debt Instrument, Periodic Payment					1
Debt Instrument, Interest Rate, Stated Percentage		1.90%			1.90%
Other Notes Payable														19	41
Eurodollar [Member] | Revolving Credit Facility [Member]
Debt Instrument, Basis Spread on Variable Rate		2.75%
Revolving Credit Facility [Member] | Minimum [Member] | PNC Bank [Member]
Line of Credit Facility, Interest Rate at Period End		3.25%			3.25%
Revolving Credit Facility [Member]
Line of Credit Facility, Interest Rate at Period End		3.25%			3.25%							3.25%
Line of Credit Facility, Maximum Borrowing Capacity	8,000
Convertible Line of Credit Note [Member] | Minimum [Member] | PNC Bank [Member]
Line of Credit Facility, Interest Rate at Period End		3.43%			3.43%
Convertible Line of Credit Note [Member]
Line of Credit Facility, Interest Rate at Period End		3.43%			3.43%
Line of Credit Facility, Maximum Borrowing Capacity						350
Debt Instrument, Basis Spread on Variable Rate						3.25%
Debt Instrument Convertible Aggregate Amount Advanced Trigger						350
Long-term Line of Credit		307			307
Minimum [Member] | IBio Inc [Member]
Share Price		$0.88			$0.88
Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues							60,000	60,000
Stock Issued During Period, Value, New Issues							64	64
PNC Bank [Member]
Prepayment of Loan Outstanding													293
CD Financial LLC [Member] | Default Rate [Member]
Debt Instrument, Interest Rate, Stated Percentage	10.00%
CD Financial LLC [Member]
Debt Instrument, Interest Rate, Stated Percentage	6.00%															9.50%
Debt Instrument, Face Amount																4,500
Convertible Notes Payable	5,350
Debt Instrument, Convertible, Conversion Price	$0.65
Embedded Derivative, Fair Value of Embedded Derivative Liability		15			15							717
Vitamin Realty LLC [Member]
Debt Instrument, Face Amount		686			686
E. Gerald Kay [Member]
Debt Instrument, Face Amount																	27
Marlin Leasing [Member] | Capital Lease Obligations [Member]
Debt Instrument, Interest Rate, Stated Percentage										5.60%
Marlin Leasing [Member]
Debt Instrument, Interest Rate, Stated Percentage									7.10%
Capital Lease Obligations									68	47
Capital Lease Obligation Monthly Lease Payment									2	2
Quantum Analytics [Member]
Debt Instrument, Interest Rate, Stated Percentage											0.00%
Capital Lease Obligations											138
Capital Lease Obligation Monthly Lease Payment											$8

Note_5_Senior_Credit_Facility_3

Note 5 - Senior Credit Facility, Subordinated Convertible Note, Net - CD Financial, LLC and other Long Term Debt - Debt Outstanding (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Jun. 30, 2014
Revolving advances under Senior Credit Facility with PNC Bank, National Association	$4,412	$4,121
Capital Lease Obligations	161	83
Total outstanding debt	9,320	9,068
Less: Revolving Advances	-4,412	-4,121
Current portion of long term debt	-828	-588
Long term debt	4,080	4,359
Discount for embedded derivative	-258	-341
Convertible Note payable, net - CD Financial, LLC	5,092	5,009
Revolving Credit Facility [Member] | PNC Bank [Member] | Minimum [Member]
Line of Credit Facility, Interest Rate at Period End	3.25%
Revolving Credit Facility [Member] | PNC Bank [Member]
Revolving advances under Senior Credit Facility with PNC Bank, National Association	4,412	4,121
Revolving advances under Senior Credit Facility with PNC Bank, National Association	6/27/17
Less: Revolving Advances	-4,412	-4,121
Revolving Credit Facility [Member]
Line of Credit Facility, Interest Rate at Period End	3.25%	3.25%
Convertible Line of Credit Note [Member] | PNC Bank [Member] | Minimum [Member]
Line of Credit Facility, Interest Rate at Period End	3.43%
Convertible Line of Credit Note [Member] | PNC Bank [Member]
Revolving advances under Senior Credit Facility with PNC Bank, National Association	307
Revolving advances under Senior Credit Facility with PNC Bank, National Association	5/31/18
Less: Revolving Advances	-307
Convertible Line of Credit Note [Member]
Line of Credit Facility, Interest Rate at Period End	3.43%
PNC Bank [Member] | Minimum [Member]
Installment Note with PNC Bank	3.75%
PNC Bank [Member]
Revolving advances under Senior Credit Facility with PNC Bank, National Association	6/27/17
Installment Note with PNC Bank	2,013	2,413
CD Financial LLC [Member] | Minimum [Member]
Installment Note with PNC Bank	6.00%
CD Financial LLC [Member]
Revolving advances under Senior Credit Facility with PNC Bank, National Association	7/7/17
Installment Note with PNC Bank	1,714	1,714
Vitamin Realty LLC [Member] | Minimum [Member]
Installment Note with PNC Bank	4.00%
Vitamin Realty LLC [Member]
Revolving advances under Senior Credit Facility with PNC Bank, National Association	7/7/17
Installment Note with PNC Bank	686	686
E. Gerald Kay [Member] | Minimum [Member]
Installment Note with PNC Bank	4.00%
E. Gerald Kay [Member]
Revolving advances under Senior Credit Facility with PNC Bank, National Association	7/7/17
Installment Note with PNC Bank	27	27
Acura Financial Services [Member] | Minimum [Member]
Installment Note with PNC Bank	1.90%
Acura Financial Services [Member]
Revolving advances under Senior Credit Facility with PNC Bank, National Association	4/15/17
Installment Note with PNC Bank		24
Minimum [Member] | Convertible Debt [Member]
Installment Note with PNC Bank	6.00%
Maximum [Member]
Capitalized lease maturity date	2/28/2015 - 11/20/2016
Convertible Debt [Member]
Revolving advances under Senior Credit Facility with PNC Bank, National Association	7/7/17
Installment Note with PNC Bank	$5,350	$5,350

Note_5_Senior_Credit_Facility_4

Note 5 - Senior Credit Facility, Subordinated Convertible Note, Net - CD Financial, LLC and other Long Term Debt - Calculation of Fair Value of Derivative Liability (Details) (USD $)	9 Months Ended	12 Months Ended
	Mar. 31, 2015	Jun. 30, 2014	Jun. 27, 2012
Share Price	0.08	0.25	0.09
Derivative [Member]
Risk Free Interest Rate	0.60%	0.88%	0.72%
Volatility	69.70%	88.50%	144.10%
Term (in years)	2 years 91 days	3 years	5 years
Dividend Rate	0.00%	0.00%	0.00%

Note_6_Significant_Risks_and_U1

Note 6 - Significant Risks and Uncertainties (Details Textual)	3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014	Jun. 30, 2014
Sales Revenue, Net [Member] | Customer Concentration Risk [Member] | Two Customers [Member]
Concentration Risk, Percentage	83.00%	78.00%	83.00%	80.00%
Sales Revenue, Net [Member] | Customer Concentration Risk [Member] | Major Customer 1 [Member] | Contract Manufacturing [Member]
Concentration Risk, Percentage	37.00%	58.00%	48.00%	68.00%
Sales Revenue, Net [Member] | Customer Concentration Risk [Member] | Major Customer 2 [Member] | Contract Manufacturing [Member]
Concentration Risk, Percentage	56.00%	30.00%	42.00%	21.00%
Sales Revenue, Net [Member] | Customer Concentration Risk [Member] | Major Customer 3 [Member] | Branded Proprietary Products [Member]
Concentration Risk, Percentage	82.00%	15.00%	79.00%	52.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Three Customers [Member]
Concentration Risk, Percentage	80.00%				74.00%
Number of Employees, Geographic Area [Member] | Unionized Employees Concentration Risk [Member]
Concentration Risk, Percentage			62.00%

Note_7_Commitments_and_Conting2

Note 7 - Commitments and Contingencies (Details Textual) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014	Jun. 30, 2014	Jan. 05, 2012	Jan. 04, 2012	19-May-14	15-May-12
						sqft	sqft	sqft
Operating Leases, Rent Expense	$262	$258	$759	$749
Capital Lease Obligations	161		161		83
Manhattan Drug Company [Member]
Area of Real Estate Property						76,161	74,898
Payments for Rent			533
AgroLabs [Member]
Area of Real Estate Property								2,700
Payments for Rent			27
Vitamin Realty LLC [Member]
Operating Leases, Rent Expense	223	215	637	622
Capital Lease Obligations	947		947		902
Stock Purchase Agreement [Member]
Loss Contingency, Estimate of Possible Loss									600
Environmental Issues [Member]
Loss Contingency, Estimate of Possible Loss									$300

Note_7_Minimum_Rental_Commitme

Note 7 - Minimum Rental Commitment for Long-term Non-cancelable Leases (Details) (USD $)	Mar. 31, 2015
In Thousands, unless otherwise specified
2015, remaining	$155
2016	610
2017	588
2018	577
2019	565
2020	564
Thereafter	3,080
Total	6,139
Non-related Party [Member]
2015, remaining	14
2016	47
2017	25
2018	14
2019	2
2020	1
Total	103
Principal Owner [Member]
2015, remaining	141
2016	563
2017	563
2018	563
2019	563
2020	563
Thereafter	3,080
Total	$6,036

Note_8_Related_Party_Transacti1

Note 8 - Related Party Transactions (Details Textual) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2013	Jun. 27, 2012
Earnings Before Interest Taxes Depreciation and Amortization	$1.50
Director [Member]
Guarantor Obligations, Current Carrying Value		1
Chief Executive Officer [Member]
Guarantor Obligations, Current Carrying Value		1
Majority Shareholder [Member]
Guarantor Obligations, Current Carrying Value		$1

Note_9_Segment_Information_Det

Note 9 - Segment Information (Details Textual) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Number of Reportable Segments			3
Europe and Canada [Member]
Revenues	$2,174	$2,113	$6,570	$8,369

Note_9_Segment_Information_Ope

Note 9 - Segment Information - Operations by Business Segment (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Sales, net	$9,671	$7,522	$28,544	$25,501
Gross profit	899	727	3,456	3,793
Depreciation	71	60	202	195
Capital expenditures	39	86	413	168
Contract Manufacturing [Member] | UNITED STATES
Sales, net	6,893	4,713	20,272	15,115
Contract Manufacturing [Member] | International Customers [Member]
Sales, net	1,805	2,058	5,876	7,739
Contract Manufacturing [Member]
Sales, net	8,698	6,771	26,148	22,854
Gross profit	681	643	2,965	3,217
Depreciation	70	57	200	185
Capital expenditures	39	86	412	166
Branded Proprietary Products [Member] | UNITED STATES
Sales, net	82	147	280	409
Branded Proprietary Products [Member] | International Customers [Member]
Sales, net	300	45	586	527
Branded Proprietary Products [Member]
Sales, net	382	192	866	936
Gross profit	-5	-64	-74	100
Depreciation		1	1	2
Capital expenditures			1
Other Nutraceutical Business [Member] | UNITED STATES
Sales, net	522	549	1,422	1,608
Other Nutraceutical Business [Member] | International Customers [Member]
Sales, net	69	10	108	103
Other Nutraceutical Business [Member]
Sales, net	591	559	1,530	1,711
Gross profit	223	148	565	476
Depreciation	1	2	1	8
Capital expenditures				2
UNITED STATES
Sales, net	7,497	5,409	21,974	17,132
International Customers [Member]
Sales, net	$2,174	$2,113	$6,570	$8,369

Note_9_Reconciliation_of_Asset

Note 9 - Reconciliation of Assets from Segment to Consolidated (Details) (USD $)	Mar. 31, 2015	Jun. 30, 2014
In Thousands, unless otherwise specified
Assets	$12,420	$11,583
Contract Manufacturing [Member]
Assets	9,021	7,752
Branded Proprietary Products [Member]
Assets	1,441	1,781
Other Nutraceutical Business [Member]
Assets	$1,958	$2,050